Related Experiment Video
Updated: May 23, 2026

Generation of Induced Pluripotent Stem Cell-Derived iTenocytes via Combined Scleraxis Overexpression and 2D Uniaxial Tension
Published on: March 1, 2024
CXCL10-LACTC1/C2 Expressing Mesenchymal Stem Cell Conditioned Medium Attenuates TNF-α-Induced Gene Expressions and
Kaya Molo1,2, Ruken Ege1, Kübra Ati̇k1
1Faculty of Science and Letters, Department of Molecular Biology and Genetics, Yıldız Technical University, Istanbul, 34220, Turkey.
Insights
Engineered mesenchymal stem cells (MSCs) expressing CXCL10 showed enhanced immunomodulatory functions. This strategy offers potential for treating inflammation in atherosclerosis and vascular injury.
Area of Science:
- Immunology
- Regenerative Medicine
- Vascular Biology
Background:
- Infectious diseases worsen atherosclerosis via sustained inflammation and elevated cytokines like CXCL10.
- CXCL10 recruits immune cells, promoting endothelial dysfunction and disease progression.
- Mesenchymal stem cells (MSCs) secrete CXCL10, but its role in MSC immunomodulation is unclear.
Purpose of the Study:
- To investigate if CXCL10 signaling modulates MSC-mediated immunoregulation.
- To engineer MSCs for localized, sustained CXCL10 presentation.
- To assess the impact on MSC immunomodulatory mediator expression and endothelial cell responses.
Main Methods:
- Genetically engineered Wharton's jelly-derived MSCs (WJ-MSCs) to express a membrane-anchored CXCL10-Lactadherin C1/C2 fusion protein (CXCL10-LACTC1/C2).
- Cultured engineered MSCs and analyzed immunoregulatory mediator expression (IDO1, TGF-β1, IL4I1).
- Assessed conditioned medium from engineered MSCs on TNF-α-stimulated human umbilical vein endothelial cells (HUVECs), evaluating inflammatory markers and cell viability.
Main Results:
- CXCL10-LACTC1/C2-expressing MSCs showed increased expression of IDO1, TGF-β1, and IL4I1.
- Conditioned medium from engineered MSCs attenuated TNF-α-induced inflammatory responses in HUVECs.
- Key endothelial activation and homeostasis markers (ICAM-1, PECAM-1, KDR, vWF, NRF2) were modulated, and HUVEC viability improved.
Conclusions:
- CXCL10 signaling can enhance MSC immunomodulatory programming.
- Membrane-anchored CXCL10 expression in MSCs boosts their therapeutic potential.
- Findings support MSC-based or cell-free therapies for CXCL10-driven inflammation in vascular diseases.
Abstract:
Infectious diseases exacerbate atherosclerosis-associated morbidity and mortality by inducing sustained inflammatory responses characterized by elevated IL-6, TNF-α, IFN-γ, and CXCL10. Persistent CXCL10-driven recruitment of CXCR3⁺ immune cells promotes endothelial dysfunction and atherosclerotic progression. Although mesenchymal stem cells (MSCs) respond to inflammatory cues and secrete CXCL10, the contribution of CXCL10/CXCR3 signaling to intrinsic MSC immunomodulatory programming remains poorly understood. The objective of this study is to investigate whether CXCL10 signaling can modulate MSC-mediated immunoregulation. To address this, Wharton's jelly-derived MSCs (WJ-MSCs) were genetically engineered to express a membrane-anchored CXCL10-Lactadherin C1/C2 fusion protein (CXCL10-LACTC1/C2). This strategy was designed to recapitulate physiological, localized, and sustained CXCL10 signaling, enabling spatially restricted chemokine presentation that more closely mimics cell-associated CXCL10 in inflammatory microenvironments compared with soluble CXCL10. The Lactadherin C1/C2 domain was selected to achieve stable, physiological membrane anchoring without introducing artificial transmembrane domains or compromising CXCL10 bioactivity. CXCL10-LACTC1/C2-expressing MSCs exhibited increased expression of key immunoregulatory mediators, including IDO1, TGF-β1, and IL4I1. Furthermore, conditioned medium derived from these MSCs attenuated TNF-α-induced inflammatory responses in human umbilical vein endothelial cells (HUVECs), as indicated by the modulation of endothelial activation and homeostasis markers (ICAM-1, PECAM-1, KDR, vWF, and NRF2) and improvement of cell viability. Collectively, these findings provide mechanistic insight into CXCL10-mediated MSC immunoregulation and support further investigation of MSC-based and cell-free therapeutic strategies aimed at mitigating CXCL10-driven endothelial inflammation in infection-associated vascular injury and atherosclerotic disease progression.
Related Concept Videos
Mesenchymal Stem Cells
Regulation of Hematopoietic Stem Cells